Physician profile
Jordan E Krbec
NPI 1093174278
$8,903.12
in general payments reported to CMS, 2019-2025
25 companies · $2,743 in 2025
The $2,743 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.97 · 2022: $320 · 2023: $3,131 · 2024: $2,671 · 2025: $2,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,304 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,303.91 |
| Education | $242.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,475.62 | 2023-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $1,438.54 | 2022-2025 | |
| Ucb, INC. | $960.78 | 2022-2025 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $869.60 | 2023-2025 | Ofev, Cyltezo |
| Astrazeneca Pharmaceuticals LP | $690.79 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $623.15 | 2022-2025 | |
| Janssen Biotech, INC. | $614.49 | 2022-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $417.40 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $301.44 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $278.47 | 2022-2024 | Acthar |
| Lilly USA, LLC | $245.33 | 2022-2024 | Taltz |
| Horizon Therapeutics Plc | $216.66 | 2022-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $159.21 | 2023-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $116.69 | 2024-2025 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $103.76 | 2024 | Orencia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $95.11 | 2023-2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $91.10 | 2023-2025 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $51.16 | 2023 | Opsumit |
| Radius Health, INC. | $32.36 | 2023 | Tymlos |
| Abbott Laboratories | $24.13 | 2023 | Proclaim |
| Medtronic, INC. | $23.59 | 2023 | Synchromedii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.80 | 2024 | Relistor |
| Eisai INC. | $21.09 | 2021 | |
| Bioventus LLC | $15.88 | 2021 | |
| Sandoz INC. | $13.97 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Krbec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.